Isolation and development of DNY-mAB biologic to treat Rabies Lyssavirus with the use of cGXP.

We manufactured a mock monoclonal antibody, DNY-mAB, to treat the rabies virus. We emphasize the most strategic way to undergo the manufacturing process using GxPs, critical to the biologic industry and the production of our antibody to ensure purity, quality, and identity.